Product logins

Find logins to all Clarivate products below.


Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, AbbVie’s Rinvoq) earlier in the treatment algorithm. Additionally, the availability of Pfizer’s Xeljanz / Xeljanz XR, BMS’s Zeposia, Alfasigma’s Jyseleca, Pfizer’s Velsipity, and Eli Lilly’s Omvoh has expanded the treatment armamentarium and intensified market competition. Furthermore, the recent approvals of AbbVie’s Skyrizi and Johnson & Johnson Innovative Medicine’s Tremfya and the expected launch of several therapies with novel mechanisms of action (e.g., ABX464, ivarmacitinib, MK-7240) will drive market growth over the next 10 years. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of less expensive biosimilars.

QUESTIONS ANSWERED

  • What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
  • How do gastroenterologists perceive biosimilar agents, and what has been / will be their impact on the UC market?
  • What are experts’ insights into current treatments for TNF-refractory UC (e.g., Pfizer’s Xeljanz / Xeljanz XR, Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, AbbVie’s Rinvoq, BMS’s Zeposia, Alfasigma’s Jyseleca, Pfizer’s Velsipity, Eli Lilly’s Omvoh, AbbVie’s Skyrizi, Johnson & Johnson Innovative Medicine’s Tremfya)? What factors drive their treatment decisions?
  • What are experts’ perceptions of key emerging therapies (e.g., Abivax’s ABX464, Merck’s MK-7240), and where do they see these agents fitting into the treatment algorithm?
  • How will the market evolve over the next 10 years?

CONTENT HIGHLIGHTS

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 27 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of UC by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key UC therapies through 2034, segmented by brands / generics / biosimilars, and acute and maintenance settings.

Drug treatments: Coverage of key current and emerging therapies

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…